Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children.
For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.
TOPICS INCLUDE Antimicrobial Therapy by Clinical Syndromes Antimicrobial Therapy for Neonates Choosing Among Antibiotics Antifungal Agents Antiviral Agents Antiparasitic Agents Oral Step-down Therapy for Serious Infections Prevention of Symptomatic Infection Approach to Antibiotic Allergies Antibiotic Stewardship New in the 28th Edition Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022 Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptible Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children New dosing for posaconazole suspension formulation New approaches to mucormycosis Added baloxavir for children 12+ years old Online updates of COVID-19 therapies once emergency use authorization in children at (http://www.aap.org/nelsons) http://www.aap.org/nelsons Updated Nelson’s app also available

lgli/2022 Nelsons Pediatric Antimicrobial Therapy, 28e (April 1, 2022)_(1610025644)_(American Academy of Pediatrics).pdf

lgrsnf/2022 Nelsons Pediatric Antimicrobial Therapy, 28e (April 1, 2022)_(1610025644)_(American Academy of Pediatrics).pdf

zlib/Medicine/Pediatrics/John S. Bradley/2022 Nelson's Pediatric Antimicrobial Therapy_21594891.pdf

John S. Bradley, Nelson, John D., Barnett Elizabeth, Joseph B. Cantey, David W. Kimberlin

John S Bradley; John D Nelson; Elizabeth D Barnett

United States, United States of America

28th edition, Itasca, IL, 2022

Twenty-eighth, 2022

{"edition":"28","isbns":["1610025644","9781610025645"],"last_page":366,"publisher":"American Academy of Pediatrics"}

Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children.
For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.
* Antimicrobial Therapy by Clinical Syndromes
* Antimicrobial Therapy for Neonates
* Choosing Among
+ Antibiotics
+ Antifungal Agents
+ Antiviral Agents
+ Antiparasitic Agents
* Oral Step-down Therapy for Serious Infections
* Prevention of Symptomatic Infection
* Approach to Antibiotic Allergies
* Antibiotic Stewardship
* Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections
* Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022
* Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptible
* Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children
* New dosing for posaconazole suspension formulation
* New approaches to mucormycosis
* Added baloxavir for children 12+ years old
* Online updates of COVID-19 therapies once emergency use authorization in children at [http://www.aap.org/nelsons
+ Updated Nelson’s app also available](http://www.aap.org/nelsons)

Front Matter
1. Antimicrobial Therapy According to Clinical Syndromes
2. Antimicrobial Therapy for Neonates
3. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens
4. Choosing Among Antibiotics Within a Class: Beta-lactams and Beta-lactamase Inhibitors, Macrolides, Aminoglycosides, and Fluoroquinolones
5. Preferred Therapy for Specific Fungal Pathogens
6. Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins
7. Preferred Therapy for Specific Viral Pathogens
8. Choosing Among Antiviral Agents
9. Preferred Therapy for Specific Parasitic Pathogens
10. Choosing Among Antiparasitic Agents: Antimalarial Drugs, Nitroimidazoles, Benzimidazoles, and Neglected Tropical Diseases
11. How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes
12. Approach to Antibiotic Therapy for Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus
13. Antibiotic Therapy for Children Who Are Obese
14. Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections
15. Antimicrobial Prophylaxis/Prevention of Symptomatic Infection
16. Approach to Antibiotic Allergies
17. Antibiotic Stewardship
18. Systemic and Topical Antimicrobial Dosing and Dose Forms
Appendix: Nomogram for Determining Body Surface Area
References
Index

2022-05-18